Article
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Breast cancer research and treatment - 1 Oct 2013
Ruddy Kathryn J, Desantis Stephen D, Gelman Rebecca S, Wu Alan H B, Punglia Rinaa S, Mayer Erica L, Tolaney Sara M, Winer Eric P, Partridge Ann H, Burstein Harold J
Abstract excerpt
Tamoxifen is metabolized into endoxifen, a potent antagonist of the estrogen receptor, in part through cytochrome p450 (CYP) 2D6. Genotypic variation in CYP2D6 affects endoxifen levels, and some have argued that patients who do not efficiently metabolize tamoxifen might wish to consider alternative hormonal treatments. This study evaluated an algorithm in which endoxifen levels and CYP2D6 genotypes were used to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.